nby20240606

0001437749-24-019536.txt : 20240607 0001437749-24-019536.hdr.sgml : 20240607 20240607073013 ACCESSION NUMBER: 0001437749-24-019536 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240604 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovaBay Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001389545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680454536 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33678 FILM NUMBER: 241027370 BUSINESS ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 899-8800 MAIL ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 8-K 1 nby20240606_8k.htm FORM 8-K nby20240606_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of earliest event reported: June 4, 2024

NovaBay Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33678	68-0454536
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2000 Powell Street, Suite 1150, Emeryville, CA 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 899-8800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange On Which Registered
Common Stock, par value $0.01 per share		NBY		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On June 4, 2024, NovaBay Pharmaceuticals, Inc. (the “Company”) was notified by NYSE American LLC (“NYSE American”) that the Company’s plan to regain compliance with NYSE American’s continued listing standards had been accepted.

As previously disclosed, the Company was notified by NYSE American on April 18, 2024 and May 28, 2024 that it is not in compliance with the continued listing standards of the NYSE American Company Guide (the “Company Guide”) set forth in Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide, requiring a listed company to have stockholders’ equity of (i) at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years; (ii) at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years; and (iii) at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively.

The Company was required to submit a plan to NYSE American by May 18, 2024 addressing how it intends to regain compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide by October 18, 2025. The Company submitted a plan prior to the deadline. On June 4, 2024, the Company received notice from NYSE American that it had accepted the Company’s plan and granted a plan period through October 18, 2025. During the plan period, the Company will be subject to quarterly monitoring for compliance with the plan. If the Company does not regain compliance with NYSE American’s listing standards by October 18, 2025, or if the Company does not make progress consistent with its plan, then NYSE American may initiate delisting proceedings.

The Company’s common stock will continue to be listed on NYSE American during the plan period under the symbol “NBY” with a “below compliance” indicator appended to the Company’s ticker symbol (with the added designation of “.BC”). The Company’s receipt of the notification from NYSE American accepting the compliance plan does not affect the Company’s business operations or its reporting requirements with the U.S. Securities and Exchange Commission.

On June 7, 2024, the Company issued a press release disclosing the receipt of NYSE American’s notice accepting the Company’s compliance plan, a copy of which is filed as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated June 7, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NovaBay Pharmaceuticals, Inc.


	By:	/s/ Justin Hall
		Justin Hall
		Chief Executive Officer and General Counsel

Dated: June 7, 2024

EX-99.1 2 ex_684481.htm EXHIBIT 99.1 ex_684481.htm

Exhibit 99.1

NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American

EMERYVILLE, Calif. (June 7, 2024) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announces that the NYSE American LLC (“NYSE American”) has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards.

“I’m pleased to report on our forward momentum. By divesting an unprofitable business segment earlier this year, we’re now able to focus solely on our core competency in eyecare,” said Justin Hall, CEO of NovaBay. “Unshackled by past burdens, we are positioned for growth in the large U.S. eyecare market with our established, high-quality Avenova®-branded products, effective and cost-efficient digital marketing programs, and loyal customer base. This is an exciting and transformative time for the Company.”

The NYSE American has reviewed NovaBay’s compliance plan and information submitted on May 8, 2024 and determined that the Company made a reasonable demonstration of its ability to make substantial progress toward regaining compliance by October 18, 2025. During this time, the Company will be subject to quarterly monitoring for compliance with the plan. If the Company does not regain compliance with NYSE American’s listing standards by October 18, 2025, or if the Company does not make sufficient progress consistent with its plan, then the NYSE American may initiate delisting proceedings at that time.

As previously disclosed, the NYSE American notified the Company on April 18, 2024 and May 28, 2024 that it was not in compliance with the continued listing standards of the NYSE American Company Guide. Specifically, the notifications indicated that the Company was not in compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide, requiring a listed company to have a certain amount of stockholders' equity. The Company’s receipt of such notification from NYSE American does not affect the Company’s business operations or its reporting requirements with the U.S. Securities and Exchange Commission.

About NovaBay Pharmaceuticals, Inc.:

NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is available directly to consumers through online distribution channels such as Amazon.com. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. NovaBay offers a full portfolio of scientifically developed products for each step of the standard dry eye treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. The Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in the United States.

NovaBay Pharmaceuticals Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our business strategies and prospects and the Company's ability to regain compliance with the continued listing requirements of NYSE American. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to the Company’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company’s latest Form 10-Q/K filings with the SEC, especially under the heading "Risk Factors". The forward-looking statements in this press release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and stay informed on NovaBay’s progress:

Like us on Facebook
Follow us on X
Connect with NovaBay on LinkedIn
Visit NovaBay's Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com

NovaBay
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com

Investors
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

# # #

EX-101.SCH 3 nby-20240604.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 nby-20240604_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 nby-20240604_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 nby-20240604_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 logo.jpg begin 644 logo.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Jun. 04, 2024
Document Information [Line Items]
Entity, Registrant Name	NovaBay Pharmaceuticals, Inc.
Document, Type	8-K
Document, Period End Date	Jun. 04, 2024
Entity, Incorporation, State or Country Code	DE
Entity, File Number	001-33678
Entity, Tax Identification Number	68-0454536
Entity, Address, Address Line One	2000 Powell Street, Suite 1150
Entity, Address, City or Town	Emeryville
Entity, Address, State or Province	CA
Entity, Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	899-8800
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	NBY
Security Exchange Name	NYSE
Entity, Emerging Growth Company	false
Amendment Flag	false
Entity, Central Index Key	0001389545

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,4[QU@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #%.\=8/G>H+.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y&!R;-I:.G#@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/ MGT"-#E+W$9]C'S"2Q70WNLXGJ<.:G8B"!$CZA$ZE,1@M(? MZHA0<;X"AZ2,(@4SL @+D;6-T5)'5-3'"][H!1\^8Y=A1@-VZ-!3 E$*8.T\ M,9S'KH$;8(811I>^"V@68J[^B\GK%M8G M4E[C]"M92>> :W:=_%IO'O=;UE:\NB_XJN />R%DS:7@[[/K#[^;L.N-/=A_ M;'P5;!OX=1?M%U!+ P04 " #%.\=8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,4[QUA=5>[.4 0 *L0 8 >&PO=V]R:W-H965T&UL ME9AK<^(V%(;_BL:=Z;0S26R92R %9@A)6KJ[62;0[FP[_2!L 9K8DBO)(?S[ M'AFPZ:PY9K_$%Z37CXZ.WB-EL%7ZU6PXM^0]3:09>AMKLSO?-]&&I\S#?3HX'*;2(DGVEB\C1E>G?/ M$[4=>M0[OG@1ZXUU+_S1(&-K/N?VCVRFX,(CZR087-[XA">)4P*.?P^B7OE-U_'T M_JC^5 P>!K-DAD]4\D7$=C/T>AZ)^8KEB7U1V]_X84 =IQ>IQ!1_R7;?MMWQ M2)0;J])#9R!(A=Q?V?LA$"<=6O1,A_#0(2RX]Q\J*!^89:.!5ENB76M0 ">DFY6YU?"K@'YV]*"B'()LR5C&Y%%:87=D*O>S#5$;^!8^XIKZT4'P M?B\8GA'\/96K^J4/< M2[;K)5VBWYF,17SH028;KM^X-_KQ!]H-?D& 6R5P"U,?[8-X15[X6ABK&: _ MLY378>)"S^J-W;,=F6T8C#OBN1412\P51"*Z04#;)6@;U3]&]HHL=EDM']Z_ M=_T!H>B4%)T+*69<"^62,":0RK5 N%21>D7N-25?MX3K7C27$'&E,Z6+[+LB M@?7N)875W]X1!!O2\3;BQ"?1,+)0(I9T 8:9!9=/!]U%/G%-# M"B[4MMZE&_12KG=O(DDXAG=21>CWX95+9*;5FY!1;50;1"=CC*TJ(!2U^V_9 M9LI8EI"_1'9VX39(]MO= %LKM"H6%#?Y8AK'L)\ZCX(+="B:8%4QH+B;?U10 M7*#6*(G92(-(K]^_[O4"E*@J#!2W\R]:6,LE!"9-7"51I[*^RGNVS/-KR,(#X<%5FR2%ES&7)// MJ]69^3;KI8)5W+Y"<5M;E7TBFUX*Z\/<6]>:!:[%)OOTJ6J3; &@>?[KQA(Y>HA M;L#'H)#']VC#Y)J?WPU M*#9E5%A9>8@[\1CR/"YR_2EAZUH47* 1I3+S$/?A8Y@F0*/!UJ>PZ-[)!UX? M(%P+]C:TU>O#]JL.S3\Y>KIC_"?FYL60A*] +;BY!6O6^Y/Q_L&JK#B-+I6% MLVUQN^$,/,$U@-]72MGC@SO@EO^?&/T'4$L#!!0 ( ,4[QUB?H!OPL0( M .(, - >&PO9KEMWDOSAR+DC MO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-B MK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@ MI+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTP MY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36 M-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO M<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#V MG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ M+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /, M)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AME ML,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>> MQ[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( M ,4[QUB7BKL

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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.nby.com/20240604/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports nby-20240604.xsd nby-20240604_def.xml nby-20240604_lab.xml nby-20240604_pre.xml nby20240606_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nby20240606_8k.htm": { "nsprefix": "nby", "nsuri": "http://www.nby.com/20240604", "dts": { "schema": { "local": [ "nby-20240604.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "nby-20240604_def.xml" ] }, "labelLink": { "local": [ "nby-20240604_lab.xml" ] }, "presentationLink": { "local": [ "nby-20240604_pre.xml" ] }, "inline": { "local": [ "nby20240606_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.nby.com/20240604/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20240606_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20240606_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.nby.com/20240604/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001437749-24-019536-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-019536-xbrl.zip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end XML 19 nby20240606_8k_htm.xml IDEA: XBRL DOCUMENT 0001389545 2024-06-04 2024-06-04 false 0001389545 8-K 2024-06-04 NovaBay Pharmaceuticals, Inc. DE 001-33678 68-0454536 2000 Powell Street, Suite 1150 Emeryville CA 94608 510 899-8800 false false false false Common Stock NBY NYSE false